BrightPath Biotherapeutics Co.Ltd.(JP:4594)
¥38.000.00 (0.00%)
JP:4594
BrightPath Biotherapeutics Co.Ltd. financials statements
¥38.00
At close:0.00 (0.00%)
Want to see JP:4594 full AI Analyst Report?
BrightPath Biotherapeutics Co.Ltd. (4594) Ratios
0 Followers
BrightPath Biotherapeutics Co.Ltd. Ratios
JP:4594's free cash flow for Q4 2025 was ¥0.00. For the 2025 fiscal year, JP:4594's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 15.83 | 8.14 | 6.18 | 21.57 | 14.60 |
| Quick Ratio | 15.83 | 8.14 | 6.18 | 21.57 | 14.60 |
| Cash Ratio | 13.36 | 6.16 | 5.54 | 20.00 | 12.48 |
| Solvency Ratio | -5.52 | -5.88 | -4.65 | -10.97 | -6.04 |
| Operating Cash Flow Ratio | -8.46 | -9.50 | -6.06 | -15.73 | -8.19 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -50.01 | -10.28 | 0.00 | -17.28 |
| Net Current Asset Value | ¥ 2.32B | ¥ 875.69M | ¥ 929.69M | ¥ 1.52B | ¥ 2.46B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.02 | 0.09 | 0.00 | 0.03 |
| Debt-to-Equity Ratio | 0.00 | 0.03 | 0.11 | 0.00 | 0.03 |
| Debt-to-Capital Ratio | 0.00 | 0.03 | 0.10 | 0.00 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.10 | 1.21 | 1.26 | 1.09 | 1.09 |
| Debt Service Coverage Ratio | 0.00 | -46.05 | -10.25 | -24079.54 | -16.49 |
| Interest Coverage Ratio | 0.00 | 0.00 | -825.65 | -24050.15 | -4077.44 |
| Debt to Market Cap | 0.00 | 0.01 | 0.03 | 0.00 | 0.02 |
| Interest Debt Per Share | 0.00 | 0.31 | 1.78 | 0.00 | 1.69 |
| Net Debt to EBITDA | 1.66 | 0.68 | 0.81 | 1.04 | 1.53 |
| Profitability Margins | |||||
| Gross Profit Margin | 65.48% | 97.18% | -473.61% | 64.11% | 78.47% |
| EBIT Margin | -1550632.14% | -101434.16% | -1619697.22% | -28099.85% | -9614.55% |
| EBITDA Margin | -1550632.14% | -101434.16% | -1619147.22% | -27783.18% | -9386.60% |
| Operating Profit Margin | -1541666.67% | -102464.08% | -1604276.39% | -27785.21% | -9579.65% |
| Pretax Profit Margin | -1550632.14% | -101434.16% | -1619697.22% | -28101.00% | -9616.90% |
| Net Profit Margin | -1553513.10% | -101601.85% | -1622336.11% | -28136.99% | -9632.61% |
| Continuous Operations Profit Margin | -1553513.10% | -101601.85% | -1622336.11% | -28136.99% | -9632.61% |
| Net Income Per EBT | 100.19% | 100.17% | 100.16% | 100.13% | 100.16% |
| EBT Per EBIT | 100.58% | 98.99% | 100.96% | 101.14% | 100.39% |
| Return on Assets (ROA) | -50.10% | -102.73% | -94.95% | -87.32% | -53.56% |
| Return on Equity (ROE) | -55.10% | -124.45% | -119.32% | -94.77% | -58.63% |
| Return on Capital Employed (ROCE) | -53.00% | -117.39% | -111.15% | -90.29% | -57.07% |
| Return on Invested Capital (ROIC) | -53.00% | -114.49% | -100.29% | -90.29% | -55.20% |
| Return on Tangible Assets | -50.10% | -102.73% | -94.95% | -87.32% | -53.56% |
| Earnings Yield | -16.95% | -32.10% | -27.58% | -14.48% | -27.71% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.02 | 12.00 | 96.00 | 0.93 |
| Payables Turnover | 0.91 | 0.91 | 20.65 | 24.61 | 1.73 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.62 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Cash Conversion Cycle | 220561.29 | 20437.35 | 12.74 | -11.03 | 182.51 |
| Days of Sales Outstanding | 220964.05 | 20836.57 | 30.42 | 3.80 | 392.91 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 402.76 | 399.22 | 17.68 | 14.83 | 210.39 |
| Operating Cycle | 220964.05 | 20836.57 | 30.42 | 3.80 | 392.91 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -12.24 | -15.34 | -18.03 | -20.19 | -29.08 |
| Free Cash Flow Per Share | -12.25 | -15.36 | -18.15 | -20.22 | -29.42 |
| Dividend Paid and CapEx Coverage Ratio | -2311.08 | -912.67 | -151.27 | -684.32 | -85.69 |
| Capital Expenditure Coverage Ratio | -2311.08 | -912.67 | -151.27 | -684.32 | -85.69 |
| Operating Cash Flow Coverage Ratio | 0.00 | -50.01 | -10.28 | 0.00 | -17.28 |
| Operating Cash Flow to Sales Ratio | -16260.13 | -1103.58 | -16068.33 | -228.11 | -98.13 |
| Free Cash Flow Yield | -17.75% | -34.90% | -27.50% | -11.75% | -28.56% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.90 | -3.12 | -3.63 | -6.91 | -3.61 |
| Price-to-Sales (P/S) Ratio | 91636.06 | 3165.29 | 58815.42 | 1943.48 | 347.57 |
| Price-to-Book (P/B) Ratio | 3.25 | 3.88 | 4.33 | 6.55 | 2.12 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.63 | -2.87 | -3.64 | -8.51 | -3.50 |
| Price-to-Operating Cash Flow Ratio | -5.64 | -2.87 | -3.66 | -8.52 | -3.54 |
| Price-to-Earnings Growth (PEG) Ratio | 0.34 | 0.14 | 0.13 | 0.54 | 0.17 |
| Enterprise Value Multiple | -4.25 | -2.44 | -2.82 | -5.95 | -2.17 |
| Enterprise Value | 5.54B | 2.80B | 3.29B | 8.73B | 3.14B |
| EV to EBITDA | -4.25 | -2.44 | -2.82 | -5.95 | -2.17 |
| EV to Sales | 65967.03 | 2472.03 | 45692.36 | 1653.52 | 203.65 |
| EV to Free Cash Flow | -4.06 | -2.24 | -2.82 | -7.24 | -2.05 |
| EV to Operating Cash Flow | -4.06 | -2.24 | -2.84 | -7.25 | -2.08 |
| Tangible Book Value Per Share | 21.23 | 11.35 | 15.26 | 26.27 | 48.69 |
| Shareholders’ Equity Per Share | 21.23 | 11.35 | 15.26 | 26.27 | 48.69 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.01 | 0.00 | 0.09 | 0.30 |
| Net Income Per Share | -11.70 | -14.12 | -18.21 | -24.90 | -28.55 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 783.82 | 0.00 | 221.30 | 73.72 |
| SG&A to Revenue | 15417.32 | 241.80 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.05 | 1.09 | 0.99 | 0.81 | 1.02 |
Currency in JPY

